See more : Theta Gold Mines Limited (TGM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of InnoCare Pharma Limited (INCPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InnoCare Pharma Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Baoding Technology Co., Ltd. (002552.SZ) Income Statement Analysis – Financial Results
- Avalon Acquisition Inc. (AVACU) Income Statement Analysis – Financial Results
- Zecotek Photonics Inc. (ZMSPF) Income Statement Analysis – Financial Results
- Takachiho Koheki Co.,Ltd. (2676.T) Income Statement Analysis – Financial Results
- Osceola Gold, Inc. (OSCI) Income Statement Analysis – Financial Results
InnoCare Pharma Limited (INCPF)
About InnoCare Pharma Limited
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 738.54M | 625.40M | 1.04B | 1.36M | 1.25M | 1.62M | 102.00K |
| Cost of Revenue | 128.44M | 143.40M | 65.67M | 39.26M | 33.74M | 0.00 | 0.00 |
| Gross Profit | 610.10M | 482.01M | 977.37M | -37.89M | -32.50M | 1.62M | 102.00K |
| Gross Profit Ratio | 82.61% | 77.07% | 93.70% | -2,778.18% | -2,606.06% | 100.00% | 100.00% |
| Research & Development | 757.25M | 639.14M | 721.58M | 402.77M | 213.12M | 149.73M | 62.88M |
| General & Administrative | 48.57M | 51.00M | 46.20M | 44.94M | 32.67M | 5.81M | 4.24M |
| Selling & Marketing | 203.55M | 438.61M | 298.46M | 68.21M | 3.46M | 558.00K | 0.00 |
| SG&A | 551.28M | 489.61M | 344.66M | 113.15M | 36.12M | 6.36M | 4.24M |
| Other Expenses | -47.28M | -287.69M | -52.29M | -175.44M | -1.97B | -415.78M | -272.69M |
| Operating Expenses | 1.26B | 1.21B | 1.14B | 495.91M | 251.88M | 150.26M | 67.12M |
| Cost & Expenses | 1.39B | 1.36B | 1.21B | 495.91M | 251.88M | 150.26M | 67.12M |
| Interest Income | 192.33M | 136.91M | 135.14M | 96.81M | 72.05M | 8.42M | 213.00K |
| Interest Expense | 35.03M | 17.05M | 2.64M | 1.14M | 938.00K | 1.45M | 2.40M |
| Depreciation & Amortization | 92.62M | 68.40M | 32.48M | 11.45M | 9.07M | 5.39M | 3.72M |
| EBITDA | -516.55M | -808.28M | 16.23M | -453.44M | -2.14B | -547.19M | -335.61M |
| EBITDA Ratio | -69.94% | -131.63% | 0.79% | -33,243.33% | -171,942.18% | -33,922.39% | -329,823.53% |
| Operating Income | -651.15M | -891.63M | -24.25M | -464.89M | -2.15B | -553.91M | -340.14M |
| Operating Income Ratio | -88.17% | -142.57% | -2.32% | -34,082.84% | -172,669.21% | -34,255.60% | -333,468.63% |
| Total Other Income/Expenses | 6.95M | -525.11K | 4.13M | 73.03M | -1.90B | -405.38M | -274.71M |
| Income Before Tax | -644.21M | -893.73M | -20.12M | -464.26M | -2.15B | -554.02M | -341.73M |
| Income Before Tax Ratio | -87.23% | -142.90% | -1.93% | -34,036.88% | -172,441.94% | -34,262.40% | -335,033.33% |
| Income Tax Expense | 1.43M | -7.13M | 46.56M | -470.00K | -8.96M | -4.07M | 0.00 |
| Net Income | -631.26M | -886.59M | -64.55M | -463.79M | -2.14B | -549.95M | -341.73M |
| Net Income Ratio | -85.47% | -141.76% | -6.19% | -34,002.42% | -171,723.18% | -34,010.51% | -335,033.33% |
| EPS | -0.37 | -0.60 | -0.04 | -0.48 | -1.21 | -0.44 | -0.27 |
| EPS Diluted | -0.37 | -0.60 | -0.04 | -0.48 | -1.21 | -0.44 | -0.27 |
| Weighted Avg Shares Out | 1.71B | 1.48B | 1.76B | 967.58M | 1.76B | 1.25B | 1.25B |
| Weighted Avg Shares Out (Dil) | 1.71B | 1.48B | 1.76B | 967.58M | 1.76B | 1.25B | 1.25B |
Source: https://incomestatements.info
Category: Stock Reports